Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?

Ferguson, L.D. and Sattar, N. (2013) Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted? Diabetes, Obesity and Metabolism, 15(5), pp. 387-391. (doi:10.1111/dom.12018)

Full text not currently available from Enlighten.

Abstract

Cardiovascular disease remains a major source of morbidity and mortality in type 2 diabetes mellitus. This article examines the recent evidence from trials and related meta-analyses on the effects of glycaemic control on cardiovascular disease (and, to a lesser extent, microvascular outcomes) in diabetes, and compares this with evidence accrued from blood pressure and statin trials. On the basis of such evidence, as well pragmatic considerations, it is clear that clinicians should place stronger emphasis on lipid, blood pressure management and lifestyle changes to lessen cardiovascular risks. At the same time, cardiovascular disease benefits of glycaemia reduction appear less pronounced, with patient characteristics critically influencing risk to benefit ratio. Recent guidelines now reflect recent observations on glycaemic control (with relaxed targets in specific patient groups), whereas future guidelines should encourage physicians to prioritise lipid-lowering and blood pressure management in patients with diabetes.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Ferguson, Dr Lyn and Sattar, Professor Naveed
Authors: Ferguson, L.D., and Sattar, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Diabetes, Obesity and Metabolism
Publisher:Wiley
ISSN:1462-8902
ISSN (Online):1463-1326
Published Online:01 November 2012

University Staff: Request a correction | Enlighten Editors: Update this record